NASDAQ:AGMB AgomAb Therapeutics Q2 2026 Earnings Report $14.83 +1.17 (+8.57%) As of 09/3/2026 04:00 PM Eastern ProfileEarnings HistoryForecast AgomAb Therapeutics EPS ResultsActual EPS-$0.46Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAgomAb Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAgomAb Therapeutics Announcement DetailsQuarterQ2 2026Date8/6/2026TimeAfter Market ClosesConference Call DateThursday, August 6, 2026Conference Call Time4:00PM ETConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) AgomAb Therapeutics Earnings HeadlinesAgomab to Participate in Upcoming Investor ConferencesSeptember 3 at 4:05 PM | globenewswire.comAnalysts’ Top Healthcare Picks: Clinuvel Pharmaceuticals (CLVLF), AgomAb Therapeutics NV ADR (AGMB)September 1 at 9:56 AM | theglobeandmail.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits. | Porter & Company (Ad)AgomAb Therapeutics (NASDAQ:AGMB) Research Coverage Started at Piper SandlerAugust 28, 2026 | americanbankingnews.comMorgan Stanley Gives a Buy Rating to AgomAb Therapeutics NV ADR (AGMB)August 25, 2026 | theglobeandmail.comAgomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of DirectorsAugust 11, 2026 | markets.businessinsider.comSee More AgomAb Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AgomAb Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AgomAb Therapeutics and other key companies, straight to your email. Email Address About AgomAb TherapeuticsAgomAb Therapeutics (NASDAQ:AGMB) (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company's name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies. AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones. The company emphasizes creating antibody formats that mimic or enhance natural ligand-receptor interactions to restore or improve biological signaling. While specific programs and indications evolve with research and regulatory progress, AgomAb’s platform is positioned to address therapeutic areas that may benefit from receptor activation rather than inhibition. AgomAb conducts its research and development through in-house scientific teams and may pursue strategic partnerships or collaborations to advance lead candidates toward clinical testing and commercialization. Public disclosures such as SEC filings, company press releases and investor presentations are the primary sources for up-to-date information on the company’s pipeline, program timelines, corporate leadership and geographic footprint. Investors and analysts should consult those documents for specific details about AgomAb’s ongoing programs and corporate developments. View AgomAb Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth StoryPalo Alto Networks Is Expensive—But Its Growth Is AcceleratingMongoDB’s Spending Fears Collide With a Much Stronger Growth StoryGitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse TestWith the RSI at a Record Low, Is It Time to Go Bargain Hunting on Burlington?Enova’s Earnings Surge Meets a Valuation Test Upcoming Earnings Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
